Breaking News, Trials & Filings

Novo Nordisk Diabetes Drug Approved in EU

The European Commission has granted marketing authorization for Novo Nordisk's Victoza for the treatment of type 2 diabetes in adults

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The European Commission has granted marketing authorization for Novo Nordisk’s Victoza for the treatment of type 2 diabetes in adults. The authorization covers all 27 European Union member states. Victoza is the brand name approved in Europe for liraglutide, the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. The authorization covers: combination treatment with metformin or a sulphonylurea in patients with insufficie...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters